205 related articles for article (PubMed ID: 26974844)
1. New developments in prostate cancer biomarkers.
Martin NE
Curr Opin Oncol; 2016 May; 28(3):248-52. PubMed ID: 26974844
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic associations of gene expression signatures in prostate cancer tissue.
Nguyen HG; Welty CJ; Cooperberg MR
Curr Opin Urol; 2015 Jan; 25(1):65-70. PubMed ID: 25405934
[TBL] [Abstract][Full Text] [Related]
3. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
4. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline.
Eggener SE; Rumble RB; Armstrong AJ; Morgan TM; Crispino T; Cornford P; van der Kwast T; Grignon DJ; Rai AJ; Agarwal N; Klein EA; Den RB; Beltran H
J Clin Oncol; 2020 May; 38(13):1474-1494. PubMed ID: 31829902
[TBL] [Abstract][Full Text] [Related]
5. An overview of biomarkers in the diagnosis and management of prostate cancer.
Uhr A; Glick L; Gomella LG
Can J Urol; 2020 Aug; 27(S3):24-27. PubMed ID: 32875999
[TBL] [Abstract][Full Text] [Related]
6. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
[TBL] [Abstract][Full Text] [Related]
7. Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy.
Cantiello F; Russo GI; Ferro M; Cicione A; Cimino S; Favilla V; Perdonà S; Bottero D; Terracciano D; De Cobelli O; Morgia G; Damiano R
Urol Oncol; 2015 Apr; 33(4):163.e15-23. PubMed ID: 25575715
[TBL] [Abstract][Full Text] [Related]
8. Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice.
Narayan VM; Konety BR; Warlick C
Int J Urol; 2017 May; 24(5):352-360. PubMed ID: 28345187
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer.
Roth JA; Ramsey SD; Carlson JJ
Oncologist; 2015 Dec; 20(12):1355-64. PubMed ID: 26482553
[TBL] [Abstract][Full Text] [Related]
10. The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy.
Wolters T; Vissers KJ; Bangma CH; Schröder FH; van Leenders GJ
BJU Int; 2010 Jul; 106(2):280-6. PubMed ID: 19888978
[TBL] [Abstract][Full Text] [Related]
11. Association of plasma intermedin levels with progression and metastasis in men after radical prostatectomy for localized prostatic cancer.
Wang XL; Wang YY; He HD; Xie X; Yu ZJ; Pan YM
Cancer Biomark; 2015; 15(6):799-805. PubMed ID: 26406405
[TBL] [Abstract][Full Text] [Related]
12. Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes.
Khani F; Epstein JI
Am J Surg Pathol; 2015 Oct; 39(10):1383-9. PubMed ID: 26076065
[TBL] [Abstract][Full Text] [Related]
13. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
14. New biomarkers in prostate cancer.
Crawford ED; Ventii K; Shore ND
Oncology (Williston Park); 2014 Feb; 28(2):135-42. PubMed ID: 24701701
[TBL] [Abstract][Full Text] [Related]
15. Molecular Profiles of Prostate Cancer: To Treat or Not to Treat.
Sternberg IA; Vela I; Scardino PT
Annu Rev Med; 2016; 67():119-35. PubMed ID: 26515982
[TBL] [Abstract][Full Text] [Related]
16. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
Benko G; Spajić B; Krušlin B; Tomas D
Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
[TBL] [Abstract][Full Text] [Related]
17. NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer.
Berlin A; Lalonde E; Sykes J; Zafarana G; Chu KC; Ramnarine VR; Ishkanian A; Sendorek DH; Pasic I; Lam WL; Jurisica I; van der Kwast T; Milosevic M; Boutros PC; Bristow RG
Oncotarget; 2014 Nov; 5(22):11081-90. PubMed ID: 25415046
[TBL] [Abstract][Full Text] [Related]
18. KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy.
Stein J; Majores M; Rohde M; Lim S; Schneider S; Krappe E; Ellinger J; Dietel M; Stephan C; Jung K; Perner S; Kristiansen G; Kirfel J
Am J Pathol; 2014 Sep; 184(9):2430-7. PubMed ID: 25016185
[TBL] [Abstract][Full Text] [Related]
19. Commercialized biomarkers: new horizons in prostate cancer diagnostics.
Murphy L; Prencipe M; Gallagher WM; Watson RW
Expert Rev Mol Diagn; 2015 Apr; 15(4):491-503. PubMed ID: 25711191
[TBL] [Abstract][Full Text] [Related]
20. Emerging biomarkers in the detection and prognosis of prostate cancer.
Filella X; Foj L
Clin Chem Lab Med; 2015 Jun; 53(7):963-73. PubMed ID: 25581761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
